SG11202106507RA - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith - Google Patents
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithInfo
- Publication number
- SG11202106507RA SG11202106507RA SG11202106507RA SG11202106507RA SG11202106507RA SG 11202106507R A SG11202106507R A SG 11202106507RA SG 11202106507R A SG11202106507R A SG 11202106507RA SG 11202106507R A SG11202106507R A SG 11202106507RA SG 11202106507R A SG11202106507R A SG 11202106507RA
- Authority
- SG
- Singapore
- Prior art keywords
- aminophenyl
- piperidine
- amino
- substituted
- compositions
- Prior art date
Links
- HWWKOVGSUZFLBU-UHFFFAOYSA-N NC1=CC=CC(NC2C(NC(=O)CC2)=O)=C1 Chemical class NC1=CC=CC(NC2C(NC(=O)CC2)=O)=C1 HWWKOVGSUZFLBU-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782298P | 2018-12-19 | 2018-12-19 | |
| US201962879900P | 2019-07-29 | 2019-07-29 | |
| PCT/US2019/067088 WO2020132014A1 (en) | 2018-12-19 | 2019-12-18 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106507RA true SG11202106507RA (en) | 2021-07-29 |
Family
ID=71098067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106507RA SG11202106507RA (en) | 2018-12-19 | 2019-12-18 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11149007B2 (en) |
| EP (1) | EP3897636A4 (en) |
| KR (1) | KR20210118816A (en) |
| CN (1) | CN113453681A (en) |
| AU (1) | AU2019403207A1 (en) |
| BR (1) | BR112021011968A2 (en) |
| CA (1) | CA3124130A1 (en) |
| CL (1) | CL2021001665A1 (en) |
| CO (1) | CO2021007973A2 (en) |
| IL (1) | IL284223A (en) |
| MX (1) | MX2021007473A (en) |
| PE (1) | PE20212247A1 (en) |
| SG (1) | SG11202106507RA (en) |
| TW (1) | TWI820276B (en) |
| WO (1) | WO2020132014A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020132016A1 (en) | 2018-12-19 | 2020-06-25 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
| KR20210118816A (en) * | 2018-12-19 | 2021-10-01 | 셀진 코포레이션 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment using same |
| PE20221582A1 (en) | 2019-12-19 | 2022-10-06 | Arvinas Operations Inc | COMPOUNDS AND METHODS FOR DIRECTED DEGRADATION OF ANDROGEN RECEPTOR |
| CA3182325A1 (en) * | 2020-06-24 | 2021-12-30 | Matthew D. Alexander | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| US11739075B2 (en) | 2020-06-24 | 2023-08-29 | Celgene Corporation | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| EP4171567A1 (en) * | 2020-06-24 | 2023-05-03 | Celgene Corporation | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| TW202227427A (en) | 2020-09-16 | 2022-07-16 | 美商拜歐斯瑞克斯公司 | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022087335A1 (en) | 2020-10-23 | 2022-04-28 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| CA3201965A1 (en) | 2020-12-14 | 2022-06-23 | Kyle W.H. Chan | Pde4 degraders, pharmaceutical compositions, and therapeutic applications |
| KR20240026939A (en) * | 2021-06-25 | 2024-02-29 | 셀진 코포레이션 | Cereblon binding compounds, compositions thereof, and methods of treatment thereby |
| EP4359406A1 (en) * | 2021-06-25 | 2024-05-01 | Celgene Corporation | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4302485A1 (en) | 1993-01-29 | 1994-08-04 | Merck Patent Gmbh | Piperazine derivatives |
| FR2768728B1 (en) | 1997-09-19 | 1999-12-03 | Rhodia Chimie Sa | PROCESS FOR ACYLATION OF AN AROMATIC COMPOUND |
| FR2768729A1 (en) | 1997-09-19 | 1999-03-26 | Rhodia Chimie Sa | A new process for the acylation of an aromatic compound |
| US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| CN101676270A (en) | 2004-09-09 | 2010-03-24 | 中外制药株式会社 | Novel imidazolidine derivative and use thereof |
| WO2007073432A2 (en) | 2005-10-11 | 2007-06-28 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| WO2007136640A2 (en) * | 2006-05-16 | 2007-11-29 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| US9163330B2 (en) | 2009-07-13 | 2015-10-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| RU2434851C1 (en) * | 2010-07-22 | 2011-11-27 | Александр Васильевич Иващенко | Cyclic n,n'-diarylthioureas or n,n'-diarylureas - antagonists of androgen receptors, anti-cancer medication, method of obtaining and application |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| US20140112922A1 (en) | 2011-03-28 | 2014-04-24 | Cornell University | Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes |
| MX358660B (en) | 2012-01-12 | 2018-08-30 | Univ Yale | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase. |
| DK2894151T3 (en) * | 2012-09-04 | 2021-01-11 | Shanghai hengrui pharmaceutical co ltd | IMIDAZOLINE DERIVATIVES, MANUFACTURING METHODS AND USE IN MEDICINE |
| WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CN105073738B (en) | 2013-01-31 | 2018-01-05 | 沃泰克斯药物股份有限公司 | Quinoline and quinoxaline amide-type as sodium channel modulators |
| RU2738833C9 (en) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Imide modulators of proteolysis and methods for using them |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RU2557235C1 (en) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Substituted 2-thioxo-imidazolidin-4-one, and spiroanalogues thereof, anticancer active ingredient, pharmaceutical composition, medicinal product, method of treating prostate cancer |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6815318B2 (en) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | How to Induce Targeted Proteolysis by Bifunctional Molecules |
| KR20230119040A (en) | 2015-01-20 | 2023-08-14 | 아비나스 오퍼레이션스, 인코포레이티드 | Compounds and Methods for the Targeted Degradation of the Androgen Receptor |
| US10730870B2 (en) | 2015-03-18 | 2020-08-04 | Arvinas Operations, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20170008904A1 (en) | 2015-07-10 | 2017-01-12 | Arvinas, Inc. | Mdm2-based modulators of proteolysis and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| TWI726969B (en) * | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | Substituted thiohydantoin derivatives as androgen receptor antagonists |
| CN109641874A (en) | 2016-05-10 | 2019-04-16 | C4医药公司 | C for target protein degradation3The glutarimide degron body of carbon connection |
| EP3481394A1 (en) * | 2016-07-08 | 2019-05-15 | Janssen Pharmaceutica N.V. | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
| TWI739888B (en) | 2016-10-07 | 2021-09-21 | 美商陶氏農業科學公司 | Pesticidal compositions and methods |
| HRP20230414T1 (en) | 2016-10-11 | 2023-07-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2018089736A1 (en) | 2016-11-10 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| US10899768B2 (en) | 2016-11-22 | 2021-01-26 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use |
| DK3524603T3 (en) | 2016-12-19 | 2022-07-04 | Abbisko Therapeutics Co Ltd | FGFR4 INHIBITORS, MANUFACTURING METHOD AND PHARMACEUTICAL APPLICATION |
| JP2020506922A (en) | 2017-01-31 | 2020-03-05 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Celebron ligands and bifunctional compounds containing cerebron ligands |
| EP3641762A4 (en) | 2017-06-20 | 2021-03-10 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN109422725A (en) | 2017-09-04 | 2019-03-05 | 北京美倍他药物研究有限公司 | Drugs for prostate cancer |
| EP3717457B1 (en) | 2017-11-28 | 2023-06-21 | Aarti Industries Limited | Process for preparation of enzalutamide using novel intermediate |
| EP3720281A4 (en) | 2017-12-05 | 2021-05-26 | Dow Agrosciences LLC | Pesticidal compositions and methods |
| CN110785423B (en) | 2018-05-30 | 2022-07-26 | 江苏豪森药业集团有限公司 | Tricyclic derivative inhibitor, preparation method and application thereof |
| CN109651256A (en) | 2018-11-20 | 2019-04-19 | 上海健康医学院 | A kind of preparation method of the miscellaneous Shandong amine of the grace of formula (VIII) |
| KR20210118816A (en) * | 2018-12-19 | 2021-10-01 | 셀진 코포레이션 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment using same |
| WO2020132016A1 (en) * | 2018-12-19 | 2020-06-25 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
-
2019
- 2019-12-18 KR KR1020217019479A patent/KR20210118816A/en unknown
- 2019-12-18 SG SG11202106507RA patent/SG11202106507RA/en unknown
- 2019-12-18 TW TW108146514A patent/TWI820276B/en active
- 2019-12-18 EP EP19901383.0A patent/EP3897636A4/en active Pending
- 2019-12-18 BR BR112021011968-0A patent/BR112021011968A2/en unknown
- 2019-12-18 CA CA3124130A patent/CA3124130A1/en active Pending
- 2019-12-18 MX MX2021007473A patent/MX2021007473A/en unknown
- 2019-12-18 CN CN201980092358.2A patent/CN113453681A/en active Pending
- 2019-12-18 WO PCT/US2019/067088 patent/WO2020132014A1/en active Application Filing
- 2019-12-18 PE PE2021000924A patent/PE20212247A1/en unknown
- 2019-12-18 AU AU2019403207A patent/AU2019403207A1/en active Pending
- 2019-12-18 US US16/719,171 patent/US11149007B2/en active Active
-
2021
- 2021-06-18 CO CONC2021/0007973A patent/CO2021007973A2/en unknown
- 2021-06-18 CL CL2021001665A patent/CL2021001665A1/en unknown
- 2021-06-20 IL IL284223A patent/IL284223A/en unknown
- 2021-08-16 US US17/403,742 patent/US11873283B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021001665A1 (en) | 2022-01-14 |
| BR112021011968A2 (en) | 2021-09-08 |
| CO2021007973A2 (en) | 2021-09-09 |
| KR20210118816A (en) | 2021-10-01 |
| EP3897636A4 (en) | 2022-09-07 |
| US11149007B2 (en) | 2021-10-19 |
| EP3897636A1 (en) | 2021-10-27 |
| CN113453681A (en) | 2021-09-28 |
| TWI820276B (en) | 2023-11-01 |
| US20200199073A1 (en) | 2020-06-25 |
| JP2022514344A (en) | 2022-02-10 |
| IL284223A (en) | 2021-08-31 |
| US20230002321A1 (en) | 2023-01-05 |
| TW202039435A (en) | 2020-11-01 |
| AU2019403207A1 (en) | 2021-07-15 |
| MX2021007473A (en) | 2021-08-05 |
| WO2020132014A1 (en) | 2020-06-25 |
| PE20212247A1 (en) | 2021-11-24 |
| US11873283B2 (en) | 2024-01-16 |
| CA3124130A1 (en) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284223A (en) | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | |
| IL284187A (en) | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | |
| MX2023004593A (en) | Tyk2 inhibitors and uses thereof. | |
| IL272748B (en) | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| IL288278A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| IL262007A (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| MX2018009773A (en) | Heteroaryl inhibitors of pad4. | |
| PH12016502523A1 (en) | Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide | |
| MX2018006700A (en) | Aza-benzimidazole inhibitors of pad4. | |
| IL283968A (en) | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
| SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| ZA202007320B (en) | Compounds for pain treatment, compositions comprising same, and methods of using same | |
| MX2021003888A (en) | Novel compounds useful for treating cardiovascular diseases. | |
| GB201915828D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| IL268318A (en) | Compounds, compositions and uses thereof for improvement of bone disorders | |
| ZA202104192B (en) | Mmpl3 inhibitors, compositions and uses thereof | |
| ZA202006591B (en) | Compositions for the treatment of hypertension | |
| SG10202108825RA (en) | Novel compositions and processes for self-assembly of block copolymers | |
| WO2015138186A3 (en) | Methods and compositions for treating anthracycline-induced cardiomyopathy using neurokinin-1 receptor antagonists | |
| IL281276A (en) | Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof | |
| EP3784226A4 (en) | Amide compounds as kinase inhibitors, compositions and methods of treatment | |
| IL284350A (en) | Domperidone compositions and methods for treating depression | |
| EA202191713A1 (en) | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, THEIR COMPOSITIONS AND THEIR TREATMENT METHODS | |
| EA202191712A1 (en) | SUBSTITUTED 3 - ((3-AMINOPHENYL) AMINO) PIPERIDINE-2,6-DIONE COMPOUNDS, THEIR COMPOSITIONS AND METHODS OF TREATMENT WITH THEIR |